The news of the death of one of the volunteers who participated in the clinical trial of the vaccine prepared by the company AstraZeneca and the University of Oxford for Covid-19 disease is making the round of the world.
As confirmed, 28-year-old doctor Joao Pedro R. Feitosa from Rio de Janeiro was the patient who died in the last 15 days due to complications from Covid-19. He was a volunteer in the Oxford vaccine research. However, the Brazilian National Health Agency (Anvisa) has not yet clarified whether he received the vaccine or placebo.
The case was revealed on Wednesday (21/10) by the newspaper “O Globo”. A few hours later, the Federal University of Rio de Janeiro announced the death of Joao Pedro Feitosa.
“The Federal University of Rio de Janeiro – along with the entire university community – expresses its sincere condolences to the family and friends of our former student,” the university said in a statement, noting that Feitosa graduated on the front lines to fight the coronavirus in the private and municipal health networks of Rio de Janeiro “.
He had not been vaccinated
According to the Brazilian media, the 28-year-old died of complications from COVID-19, on Thursday, October 15. It is not clear under what circumstances the volunteer ended up, however, according to the Bloomberg agency, the 28-year-old was not given the vaccine before his death. Reports indicate that Feitosa was not in the team that received the vaccine, while sources told Reuters that if the unfortunate doctor had died from complications of the vaccine then the trials would have been stopped. However, according to the University of Oxford and Astrazeneka, the vaccine tests will continue.
After the breaking news, a representative of the University of Oxford rushed to take a stand. In a statement to the American network CNBC, the representative, Alexander Buxton, clarified that there are no doubts about the safety of the vaccine.
The research in Brazil, despite the death of the 28-year-old, will continue, once the exact causes of death have been clarified.
Coronavirus is “hammering” Brazil, with over 154,000 deaths and 5.2 million cases. It is the second country after the United States to be hit so hard by the pandemic.
The AstraZeneca vaccine trial may resume this week in the US
AstraZeneca Plc vaccine testing for Covid-19 disease is expected to resume in the US within a week, after the US Food and Drug Administration (FDA) completed its investigation regarding the serious illness of one of the participants, four sources told Reuters.
The big trial of the vaccine in the US has been stopped since September 6, after one of the volunteers reportedly developed a rare disease, an inflammation of the spinal cord called transverse myelitis.
The sources, who asked not to be named, told the agency that they were informed that the test could resume this week. The FDA did not respond to a request for comment. It is unclear how the FDA will characterize the disease.